Congenital dyserythropoietic anemias: Molecular insights and diagnostic approach

Blood

Volumn 122, Issue 13, 2013, Pages 2162-2166

  Iolascon, Achille ^a,b   Heimpel, Hermann ^c   Wahlin, Anders ^d   Tamary, Hannah ^e,f  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF ULM   (Germany)

^d UMEÅ UNIVERSITY   (Sweden)

^e SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HEMOGLOBIN; HEPCIDIN; KIF23 PROTEIN; MITOTIC KINESIN LIKE PROTEIN 1; PROTEIN; SEC23B PROTEIN; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG;

ARTICLE; BLOOD TRANSFUSION; CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE 1; CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE 2; CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE 3; CYTOKINESIS; DNA SEQUENCE; GENE MUTATION; GENETIC CODE; GENOTYPE PHENOTYPE CORRELATION; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; IRON OVERLOAD; PRIORITY JOURNAL; SPLENECTOMY; CONGENITAL DYSERYTHROPOIETIC ANEMIA; GENETICS; REVIEW;

ANEMIA, DYSERYTHROPOIETIC, CONGENITAL; HUMANS;

EID: 84887325599     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-468223     Document Type: Article

References (51)

1. Heimpel H, Wendt F. Congenital dyserythropoietic anemia with karyorrhexis and multinuclearity of erythroblasts. Helv Med Acta. 1968;34(2):103-115.
2. Wickramasinghe SN, Wood WG. Advances in the understanding of the congenital dyserythropoietic anaemias. Br J Haematol. 2005;131(4):431-446.
3. Dgany O, Avidan N, Delaunay J, et al. Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1. Am J Hum Genet. 2002;71(6):1467-1474.
4. Schwarz K, Iolascon A, Verissimo F, et al. Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II. Nat Genet. 2009;41(8):936-940.
5. Liljeholm M, Irvine AF, Vikberg AL, et al. Congenital dyserythropoietic anemia type III (CDA III) is caused by a mutation in kinesin family member, KIF23. Blood. 2013;121(23):4791-4799.
6. Tamary H, Dgany O, Proust A, et al. Clinical and molecular variability in congenital dyserythropoietic anaemia type I. Br J Haematol. 2005;130(4):628-634.
7. Heimpel H, Kellermann K, Neuschwander N, Högel J, Schwarz K. The morphological diagnosis of congenital dyserythropoietic anemia: results of a quantitative analysis of peripheral blood and bone marrow cells. Haematologica. 2010;95(6):1034-1036.
8. Sandström H, Wahlin A. Congenital dyserythropoietic anemia type III. Haematologica. 2000;85(7):753-757.
9. Tamary H, Shalev H, Perez-Avraham G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood. 2008;112(13):5241-5244.
10. Casanovas G, Swinkels DW, Altamura S, et al. Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II. J Mol Med (Berl). 2011;89(8):811-816.
11. Lavabre-Bertrand T, Ramos J, Delfour C, et al. Long-term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I. Eur J Haematol. 2004;73(5):380-383.
12. Heimpel H, Anselstetter V, Chrobak L, et al. Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation. Blood. 2003;102(13):4576-4581.
13. Buchbinder D, Nugent D, Vu D, et al. Unrelated hematopoietic stem cell transplantation in a patient with congenital dyserythropoietic anemia and iron overload. Pediatr Transplant. 2012;16(3):E69-E73.
14. Ayas M, al-Jefri A, Baothman A, et al. Transfusion-dependent congenital dyserythropoietic anemia type I successfully treated with allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29(8):681-682.
15. Heimpel H, Schwarz K, Ebnöther M, et al. Congenital dyserythropoietic anemia type I (CDA I): molecular genetics, clinical appearance, and prognosis based on long-term observation. Blood. 2006;107(1):334-340.
16. Renella R, Roberts NA, Brown JM, et al. Codanin-1 mutations in congenital dyserythropoietic anemia type 1 affect HP1alpha localization in erythroblasts. Blood. 2011;117(25):6928-6938.
17. Ahmed MR, Chehal A, Zahed L, et al. Linkage and mutational analysis of the CDAN1 gene reveals genetic heterogeneity in congenital dyserythropoietic anemia type I. Blood. 2006;107(12):4968-4969.
18. Noy-Lotan S, Dgany O, Lahmi R, et al. Codanin-1, the protein encoded by the gene mutated in congenital dyserythropoietic anemia type I (CDAN1), is cell cycle-regulated. Haematologica. 2009;94(5):629-637.
19. Tamary H, Marcoux N, Noy-Lotan S, Yaniv I, Dgany O. Codanin-1, the product of the gene mutated in congenital dyserythropoietic anemia type I (CDA I), binds to histone chaperone Asf1a and inhibits its nucleosome assembly activity [abstract]. Blood. 2010;116(21). Abstract 1004.
20. Ask K, Jasencakova Z, Menard P, Feng Y, Almouzni G, Groth A. Codanin-1, mutated in the anaemic disease CDAI, regulates Asf1 function in S-phase histone supply. EMBO J. 2012;31(8):2013-2023.
21. Babbs C, Roberts NA, Sanchez-Pulido L, et al. Homozygous mutations in a predicted endonuclease cause congenital dyserythropoietic anemia type I [published online ahead of print May 28, 2013]. Haematologica.
22. Walkley CR, Sankaran VG, Orkin SH. Rb and hematopoiesis: stem cells to anemia. Cell Div. 2008;3:13.
23. Sankaran VG, Ludwig LS, Sicinska E, et al. Cyclin D3 coordinates the cell cycle during differentiation to regulate erythrocyte size and number. Genes Dev. 2012;26(18):2075-2087.
24. Li FX, Zhu JW, Hogan CJ, DeGregori J. Defective gene expression, S phase progression, and maturation during hematopoiesis in E2F1/E2F2 mutant mice. Mol Cell Biol. 2003;23(10):3607-3622.
25. Bianchi P, Fermo E, Vercellati C, et al. Congenital dyserythropoietic anemia type II (CDAII) is caused by mutations in the SEC23B gene. Hum Mutat. 2009;30(9):1292-1298.
26. De Matteis MA, Luini A. Mendelian disorders of membrane trafficking. N Engl J Med. 2011;365(10):927-938.
27. Iolascon A, Esposito MR, Russo R. Clinical aspects and pathogenesis of congenital dyserythropoietic anemias: from morphology to molecular approach. Haematologica. 2012;97(12):1786-1794.
28. Russo R, Gambale A, Esposito MR, et al. Two founder mutations in the SEC23B gene account for the relatively high frequency of CDA II in the Italian population. Am J Hematol. 2011;86(9):727-732.
29. Iolascon A, De Mattia D, Perrotta S, Carella M, Gasparini P, Lambertenghi Deliliers G. Genetic heterogeneity of congenital dyserythropoietic anemia type II. Blood. 1998;92(7):2593-2594.
30. Iolascon A, Russo R, Esposito MR, et al. Molecular analysis of 42 patients with congenital dyserythropoietic anemia type II: new mutations in the SEC23B gene and a search for a genotype-phenotype relationship. Haematologica. 2010;95(5):708-715.
31. Russo R, Langella C, Esposito MR, et al. Hypomorphic mutations of SEC23B gene account for mild phenotypes of congenital dyserythropoietic anemia type II. Blood Cells Mol Dis. 2013;51(1):17-21.
32. Tao J, Zhu M, Wang H, et al. SEC23B is required for the maintenance of murine professional secretory tissues. Proc Natl Acad Sci USA. 2012; 109(29):E2001-E2009.
33. Lind L, Sandström H, Wahlin A, et al. Localization of the gene for congenital dyserythropoietic anemia type III, CDAN3, to chromosome 15q21-q25. Hum Mol Genet. 1995;4(1):109-112.
34. Makyio H, Ohgi M, Takei T, et al. Structural basis for Arf6-MKLP1 complex formation on the Flemming body responsible for cytokinesis. EMBO J. 2012;31(11):2590-2603.
35. Matuliene J, Kuriyama R. Kinesin-like protein CHO1 is required for the formation of midbody matrix and the completion of cytokinesis in mammalian cells. Mol Biol Cell. 2002;13(6):1832-1845.
36. Heimpel H, Kohne E, Schrod L, Schwarz K, Wickramasinghe S. A new type of transfusion-dependent congenital dyserythropoietic anemia. Haematologica. 2007;92(10):1427-1428.
37. Gay J, Fournier M, Pierre-Eugène C, et al. New variant of unclassified congenital dyserythropoietic anaemia: the concept of the erythroid regulator? Br J Haematol. 2012;157(1):148-151.
38. Weiss MJ, Keller G, Orkin SH. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev. 1994;8(10):1184-1197.
39. Ciovacco WA, Raskind WH, Kacena MA. Human phenotypes associated with GATA-1 mutations. Gene. 2008;427(1-2):1-6.
40. Siatecka M, Bieker JJ. The multifunctional role of EKLF/KLF1 during erythropoiesis. Blood. 2011;118(8):2044-2054.
41. Singleton BK, Fairweather VS, Lau W, et al. A novel EKLF mutation in a patient with dyserythropoietic anemia: the first association of EKLF with disease in man. ASH Annual Meeting Abstracts. 2009;114(22):162.
42. Arnaud L, Saison C, Helias V, et al. A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet. 2010;87(5):721-727.
43. Ravindranath Y, Goyette G, Buck S, et al. A new case of KLF1 G973A mutation and congenital dyserythropoeitic anemia (CDA)-further definition of emerging new syndrome and possible association with gonadal dysgenesis. ASH Annual Meeting Abstracts. 2011;118(21):2101.
44. Mitchell WB, Gnanapragasam MN, Jaffray JA, Bieker JJ, Manwani D. Case report of erythroid transcription factor EKLF mutation causing a rare form of congenital dyserythropoetic anemia in a patient of Taiwanese origin. ASH Annual Meeting Abstracts. 2011;118(21):2154.
45. Jaffray JA, Mitchell WB, Gnanapragasam MN, et al. Erythroid transcription factor EKLF/KLF1 mutation causing congenital dyserythropoietic anemia type IV in a patient of Taiwanese origin: review of all reported cases and development of a clinical diagnostic paradigm. Blood Cells Mol Dis. 2013;51(2):71-75.
46. Wickramasinghe SN, Illum N, Wimberley PD. Congenital dyserythropoietic anaemia with novel intra-erythroblastic and intra-erythrocytic inclusions. Br J Haematol. 1991;79(2):322-330.
47. Majeed HA, Kalaawi M, Mohanty D, et al. Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. J Pediatr. 1989;115(5 Pt 1):730-734.
48. Ferguson PJ, Chen S, Tayeh MK, et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet. 2005;42(7):551-557.
49. Morbach H, Hedrich CM, Beer M, Girschick HJ. Autoinflammatory bone disorders. Clin Immunol. 2013;147(3):185-196.
50. Shteyer E, Saada A, Shaag A, et al. Exocrine pancreatic insufficiency, dyserythropoeitic anemia, and calvarial hyperostosis are caused by a mutation in the COX4I2 gene. Am J Hum Genet. 2009;84(3):412-417.
51. Samkari A, Borzutzky A, Fermo E, Treaba DO, Dedeoglu F, Altura RA. A novel missense mutation in MVK associated with MK deficiency and dyserythropoietic anemia. Pediatrics. 2010;125(4):e964-e968.